Mirvetuximab drug type definitions

Mirvetuximab (Mirvetuximab) is an antibody drug conjugate (ADC). The design concept of this type of drug is to combine monoclonal antibodies with cytotoxic drugs and accurately deliver them into cells by targeting antigens, thereby improving the effect of treating ovarian cancer while reducing damage to normal cells. Antibody drug conjugates utilize the specific binding function of antibodies to deliver cytotoxic drugs directly to tumor cells to achieve precise treatment.

The antibody portion of somituximab targets the folate receptorα (FRα), which is typically highly expressed on ovarian cancer cells. By targeting these cancer cells, drugs can effectively reduce damage to normal cells and therefore have higher therapeutic efficacy and lower side effects. The conjugated part of the drug is a powerful cytotoxic drug that can enter cancer cells and destroy the DNA in the cells, thereby inducing cancer cell death.

Compared with traditional chemotherapy drugs, antibody drug conjugates have higher specificity and selectivity. Chemotherapy drugs often not only act on cancer cells, but may also affect normal cells, causing serious side effects. ADC drugs reduce damage to normal tissues and significantly reduce the occurrence of adverse reactions by accurately identifying specific antigens on the surface of cancer cells. Therefore, this class of drugs has important advantages in cancer treatment, especially for patients with relapsed and drug-resistant cancers.

With the continuous development of the field of cancer treatment, the research and application of antibody drug conjugates are becoming more and more extensive, especially in various types of cancers such as ovarian cancer and breast cancer.The prospects of ADC drugs are very broad. Somituximab, as part of ADC drugs, marks further precision in anti-cancer treatment and may become a new standard for anti-ovarian cancer treatment in the future.

Reference materials:https://www.elahere.com/